# NCT02187848 (NCT02187848)

> Evaluation of SAR408701 in Patients With Advanced Solid Tumors

No report yet. It can be ordered.

- Drugs tested: tusamitamab ravtansine
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02187848
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Sanofi
- Conditions: Neoplasm Malignant
- Interventions: SAR408701
- Enrollment: 254
- Primary outcome: Number of dose limiting adverse events (every 2 week cycle)
- Primary outcome: Assessment of overall response rate using standard imaging and RECIST 1.1 criteria
- Primary outcome: Number of dose limiting adverse events (every 3 week cycle)

## Indexed commentary on NCT02187848 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02187848